The fact that a plasma factor was responsible for the stimulation of red cell production has been known for more than 35 years. However, it is only recently that the gene responsible for its production and its molecular structure has been identified. Furthermore, recombinant human erythropoietin is now available for clinical use. This article details the molecular biology and clinical pharmacology of this remarkable growth factor.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of the National Medical Association|
|State||Published - Feb 1994|
ASJC Scopus subject areas